Respiratory

According to Pfizer, the investigational vaccine to protect against Group B Streptococcus (GBS) generated maternal antibody responses against 6 capsular polysaccharide serotypes and efficiently transferred antibodies to the infants. The announcement of this phase 2 data comes in July, which is International Group B Streptococcus Month.

John Bradley, MD, medical director, infectious disease, Rady Children's Hospital, San Diego, California; professor of pediatrics, UC San Diego School of Medicine, explains how recently FDA-approved nirsevimab-alip will impact the newborn and infant RSV patient population.

The approval follows a unanimous vote of support from the FDA Antimicrobial Drugs Advisory Committee of nirsevimab-alip’s favorable benefit-risk profile for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants amid their first RSV season.

A resurgence of this infection, particularly in the pediatric population, has health care providers on alert.

A new study highlights the benefits of using the hypertonic saline test to determine the appropriate dose of inhaled corticosteroids for managing asthma in children.

Prevention and treatment strategies for tick-borne diseases and respiratory infections

Seasonal changes and COVID-19 have affected patterns in human metapneumovirus.

In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.

Devan Jaganath, MD, MPH, pediatric infectious disease physician, University of California San Francisco Benioff Children's Hospitals, explains how Hyfe AI and other artificial intelligence algorithms can detect and monitor coughing, potentially playing a role in treating RSV patients.

The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.

Nirsevimab’s efficacy against infant hospitalizations due to respiratory syncytial virus was reinforced after a phase 3b clinical trial, demonstrating an 83% reduction in infant hospitalizations.

Hidden triggers and asthma mimickers can complicate this common childhood condition.

How much progress have we made in developing therapies to treat this common childhood respiratory disorder?

New data quantify the exposure to wildfire particulate matter among schoolchildren in California, finding that interventions in a small number of schools may reduce the overall burden of wildfire PM2.5 exposure.

In a recent study, vaccination administered during pregnancy was effective against severe lower respiratory tract illness associated with respiratory syncytial virus (RSV) in infants.

New maternal vaccine options could offer extra protection in upcoming seasons.

In a recent study, the risk of death from respiratory diseases during adulthood almost doubled in individuals who experienced a lower respiratory tract infection at a young age.

A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.

The specific mechanisms involved in associations between air pollution and respiratory illness without viral infection are not understood, especially compared with those of respiratory viruses and asthma exacerbation.

Alok Patel, MD, shares what pediatric health care providers should know about a concerning new strain of group A streptococcus.

In a recent statement, the American Academy of Pediatrics discussed how patients with respiratory infections can be managed, along with guidance on RSV treatment.

Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discussed the potential threat of a “triple epidemic” of RSV, influenza, and COVID-19, and how pediatricians can identify these viruses in their communities.

Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sits down to discuss the rising threat of a "triple epidemic" consisting of influenza, COVID-19, and RSV in children.

Gregg Sylvester, MD, MPH, chief health officer at CSL Seqirus, discusses an FDA-approved cell-based flu vaccine for children as young as 6 months, trends in childhood vaccination rates, and how to prepare for the upcoming flu season.

Help your patients have a safe and healthy academic year.

For the first time, investigators broke down into narrow age bands morbidity and mortality estimates for respiratory syncytial virus (RSV).

A recent study examined the links between breastfeeding and preterm birth history with hospitalization duration due to LRTIs in infants and toddlers.

The FDA recently announced an e-cigarette prevention campaign aimed at Native American and Alaskan Native youth using prominent social media sites and traditional media like billboards, radio, and TV.

Patience and antimicrobial stewardship are key to treating sinusitis.

A new study examines the relationship between an extended duration of mother-child breastfeeding and protective associations to asthma.